Compare Dicks Sporting Goods Inc (DKS) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Incyte Corporation — how do they compare? Dicks Sporting Goods Inc trades at $136.02 (market cap $13.26B), while Incyte Corporation trades at $112.98 (market cap $22.85B). The key difference: Incyte Corporation is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Incyte Corporation for 33 Days on average.
| DKS | INCY | |
|---|---|---|
Market Cap | $13.26B | $22.85B |
Volume | 2,292,035 | 1,927,029 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $129.93 |
52-Week Low | $121.15 | $83.80 |
Typical Hold Time | 19 Days | 33 Days |
Enterprise Value | $20.31B | $18.35B |
Dividend Yield | 3.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $135.99, up 3.67% today, with a bearish technical signal but strong fundamentals including a P/E of 14.86 and ROE of 18.47%. Recent earnings show mixed results, with a Q2 2026 miss, while revenue grew to $13.44B in 2025. The stock faces headwinds from a securities class action lawsuit, but analysts maintain a buy consensus with a $153.30 price target.
The outlook is cautious due to legal risks and a bearish technical trend, but solid profitability and valuation metrics offer support. Upside potential exists if legal issues resolve and earnings rebound, though investor sentiment is tempered by near-term uncertainties. Risks include litigation outcomes and competitive pressures in retail.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
